Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | HPGD | P15428 | 4/20 | 0.52 |
| ▸ | GLA | P06280 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13139917 | 0.87 | CA12 (0.50) | ALDH1A1KDM4EHPGDGLAGAA | |
| SCHEMBL16563455 | 0.87 | ALDH1A1 (0.49) | ALDH1A1KDM4EHPGDGLAGAA | |
| SCHEMBL24369481 | 0.86 | HTT (0.53) | ALDH1A1KDM4EHPGDEPHB3SMN1; SMN2 | |
| SCHEMBL3077982 | 0.86 | ALDH1A1 (0.49) | ALDH1A1KDM4EHPGDSMN1; SMN2RAB9A | |
| SCHEMBL3074755 | 0.86 | SMN1; SMN2 (0.46) | ALDH1A1KDM4EHPGDGLAGAA | |
| SCHEMBL30935665 | 0.86 | ALDH1A1 (0.47) | ALDH1A1KDM4EHPGDGLAGAA | |
| SCHEMBL3078049 | 0.86 | SMN1; SMN2 (0.46) | ALDH1A1KDM4EHPGDGLAGAA | |
| SCHEMBL17320982 | 0.85 | EPHB3 (0.56) | ALDH1A1KDM4EHPGDGLAEPHB3 | |
| SCHEMBL22228625 | 0.85 | SMN1; SMN2 (0.45) | ALDH1A1KDM4EHPGDGLAGAA | |
| SCHEMBL3084426 | 0.85 | EPHB3 (0.54) | ALDH1A1KDM4EHPGDGLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3324977-B1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-07-13 | — | — | EP | disclosed |
| CN-108948019-B | Focal adhesion kinase inhibitors and uses thereof | 广东东阳光药业有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10865215-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-10759793-B2 | 2-(pyrazolopyridin-3-yl)pyrimidine derivatives as JAK inhibitors | ALMIRALL, S.A. (ES) | 2020-09-01 | — | — | US | disclosed |
| US-20200223867-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2020-07-16 | — | — | US | disclosed |
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2019067864-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
| EP-2927229-B1 | BENZENE-FUSED 5-MEMBERED NITROGEN-CONTAINING HETEROAROMATIC COMPOUNDS USEFUL FOR PROPHYLAXIS OR TREATMENT OF NEURODEGENERATIVE DISEASES OR EPILEPSY | TAKEDA PHARMACEUTICALS CO (JP) | 2018-09-05 | — | — | EP | disclosed |
| EP-2927229-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-10-07 | — | — | EP | disclosed |
| US-20150266872-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| US-9102671-B2 | Compounds and compositions as TRK inhibitors | NOVARTIS AG (CH) | 2015-08-11 | — | — | US | disclosed |
| WO-2015086693-A1 | PYRAZOLOPYRIMIDIN-2-YL DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2015-06-18 | — | — | WO | disclosed |
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-09-09 | — | — | US | disclosed |
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-09-09 | — | — | US | disclosed |
| EP-2176260-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009008748-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-01-15 | — | — | WO | disclosed |
| US-5200415-A | Serotonin receptor antagonists; antiemetics, antianxietics | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1993-04-06 | — | — | US | disclosed |
| EP-0483836-A1 | Pyrazolo [1,5-a] pyridine-3-carboxylic acid derivatives, their preparation process and their use | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1992-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865215-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | ALDH1A1 621/4885KDM4E 1198/4885HPGD 869/4885 |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | SERPINB1, FURIN, HIF1AN | ALDH1A1 3562/4885KDM4E 3876/4885HPGD 1593/4885 |
| US-20150266872-A1 | HETEROCYCLIC COMPOUND | HTT, BDNF, SNCA | ALDH1A1 419/4885KDM4E 1874/4885HPGD 599/4885 |
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | TP53, PNPO, DPYD | ALDH1A1 588/4885KDM4E 2333/4885HPGD 281/4885 |
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | ALDH1A1 621/4885KDM4E 1198/4885HPGD 869/4885 |
| US-10759793-B2 | 2-(pyrazolopyridin-3-yl)pyrimidine derivatives as JAK inhibitors | JAK2, JAK3, JAK1 | ALDH1A1 3554/4885KDM4E 1127/4885HPGD 1898/4885 |
| US-20200223867-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | GABRA5, GABRA1, GABBR2 | ALDH1A1 621/4885KDM4E 1198/4885HPGD 869/4885 |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | SERPINB1, FURIN, HIF1AN | ALDH1A1 3562/4885KDM4E 3876/4885HPGD 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.